AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06062576
Drug: Yunnan Baiyao
RxNorm normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks
Trial: NCT04996004
Drug: Ontorpacept (TTI-621)
RxNorm normalized name: Ontorpacept
DrugBank: Ontorpacept (DB17116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ontorpacept (TTI-621) will be administered by intravenous infusion.
Trial: NCT04300751
Drug: Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active alcohol or placebo, administered orally
Trial: NCT05262517
Drug: Rimegepant
RxNorm normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg ODT
Trial: NCT05656235
Drug: Enfortumab vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enfortumab vedotin 1.25mg/kg on Days 1 and 8 every 3 weeks for up to 35 weeks (each cycle = 21 days)
Trial: NCT05656235
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200mg on Day 1 every 3 weeks for up to 35 weeks (each cycle = 21 days)
Trial: NCT05689203
Drug: QLS1128
DrugBank: LS11 (DB05918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose 1
Trial: NCT05689203
Drug: QLS1128
DrugBank: LS11 (DB05918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose 2
Trial: NCT06520826
Drug: Vadadustat
RxNorm normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: A synthetic, orally bioavailable, small molecule being developed as an inhibitor of hypoxia-inducible factor prolyl-hydroxylases for the treatment of anemia associated with chronic kidney disease. Intervention to be administered to maintain hemoglobin within a target range of 10-11 g/dL.
Trial: NCT04981795
Drug: Tafasitamab
RxNorm normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Observational Study on safety and effectiveness of tafasitamab in combination with lenalidomide inPatients With Relapsed or Refractory DLBCL.
Trial: NCT05181124
Drug: coadministration of JP-1366 and aceclofenac
RxNorm normalized name: Acéclofénac
DrugBank: Aceclofenac (DB06736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An open-label, multiple-dosing, fixed sequence, 3-period design
Trial: NCT05966948
Drug: Dextrose Solution
RxNorm normalized name: Dextrose solution
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolotherapy is a regenerative tissue therapy that is considered efficacious for reducing the symptoms and morbidity of Knee Osteoarthritis (KOA) using hypertonic dextrose as an injectable substance. Treatment will be given two times, on day 1st and 30th day.
Trial: NCT05887804
Drug: Triamcinolone Acetonide (TA)
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 3 was injected TA 40 mg/mL/cm3, given the same injection volume (1 mL) in every cm3 keloid volume using a 1 mL syringe and 27G needle. The injections were ultrasound-guided into the center of the lesion with a 30-45-degree angle using an in-plane technique, therefore the same pressure.
Trial: NCT05325346
Drug: VLX-1005
RxNorm normalized name: VLX-1005
DrugBank: VLX-1005 (DB18307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
Trial: NCT05325346
Drug: Argatroban
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Measurement and comparison of the effects and potential interactions between VLX-1005 and argatroban on safety, tolerability, PK and PD
Trial: NCT05310422
Drug: Tivanisiran sodium ophthalmic solution
RxNorm normalized name: sodium chloride Ophthalmic Ointment
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop in the affected eye(s) once daily
Trial: NCT05310422
Drug: Vehicle ophthalmic solution
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in the affected eye(s) once daily
Trial: NCT06634823
Drug: Triamcinolone Acetonide Injectable Suspension
RxNorm normalized name: triamcinolone acetonide Injectable Suspension
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone injection into deltoid muscle (arm)
Trial: NCT06634823
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection into deltoid muscle (arm)
Trial: NCT00081055
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00081055
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05113368
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral regorafenib in a ReDOSplan (80 mg week#1, 120 mg week#2, 160 mg week#3 for cycle #1 then adjust final dose for subsequent cycles based on tolerance during cycle #1) \[3 weeks on/1 week off\] combined with intramuscular injection of fulvestrant 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
Trial: NCT05113368
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
Trial: NCT01996462
Drug: Escitalopram Oxalate Tablets
RxNorm normalized name: Escitalopram Oxalate
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05185505
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period
Trial: NCT05185505
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg/kg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period
Trial: NCT06405100
Drug: Supportive care+Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supportive care: Control blood pressure:ACEI/ARB; Diet that is low in fat and salt; Stop smoking; Moderate exercise.~Induction period: 1mg/kg/day. The maximum dose is not more than 60mg. The duration of adequate prednisone is a minimum of 4 weeks and a maximum of 16 weeks.~Maintenance period: A reduction of 5-10mg/wk was initiated after 2 weeks of complete remission and finally discontinued after 6 months of maintenance at 5mg/day.
Trial: NCT06405100
Drug: Supportive care+Tacrolimus+Ripertamab
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supportive care: Control blood pressure:ACEI/ARB; Diet that is low in fat and salt; Stop smoking; Moderate exercise.~Tacrolimus：Induction period: 0.05mg/kg/d. It will be given in two doses 12 hours apart. The blood concentration should be up to 5-10ng/ml. Maintenance therapy was initiated two weeks after complete remission; Maintenance period: Reduced to a blood concentration of 3-8ng/ml, and stopped after 6 months of maintenance treatment.~Ripertamab: Given twice every two weeks at a dose of 1000mg. 1000mg is added at 6 months.
Trial: NCT06405100
Drug: Supportive care+Ripertamab
RxNorm normalized name: Ripertamab
DrugBank: Ripertamab (DB16314)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care: Control blood pressure:ACEI/ARB; Diet that is low in fat and salt; Stop smoking; Moderate exercise.~Ripertamab: Given twice every two weeks at a dose of 1000mg. 1000mg is added at 6 months.
Trial: NCT05618808
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive enoxaparin by SC administration daily through the time of venography (or day 12, whichever is earlier)
Trial: NCT05618808
Drug: Apixiban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive apixaban orally twice a day through the time of venography (or day 12, whichever is earlier)
Trial: NCT05040490
Drug: sugammadex as reversal drugs
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: use sugammadex to reverse neuromuscular blockade
Trial: NCT05049057
Drug: Erenumab 140 Mg/mL Subcutaneous Solution
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Active erenumab delivered via subcutaneous injection.
Trial: NCT02974777
Drug: DAPT on-target
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard DAPT within the therapeutic window of platelet reactivity
Trial: NCT02974777
Drug: DAPT intensification
RxNorm normalized name: DAPT
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification of standard dose DAPT due to high platelet reactivity
Trial: NCT05048498
Drug: NEX-18a injection
RxNorm normalized name: 17-ethynyl-17-hydroxy-18a-homoestr-4-en-3-one
DrugBank: Norgestrel (DB09389)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Treatment phase 1, NEX-18a will be given as a single subcutaneous injection.~In Treatment phase 2, NEX-18a will be given as a single subcutaneous injection.
Trial: NCT05048498
Drug: Azacitidine Injection
RxNorm normalized name: azacitidine Injection
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In Treatment phase 1, azacitidine will be administered once daily for four days. In Treatment phase 2, azacitidine will be administered once daily for three days.
Trial: NCT01204411
Drug: Artesunate-amodiaquine fixed-dose combination
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * artesunate 25 mg / amodiaquine 67.5 mg: 1 tablet / day for 3 days for children with a weight of 5 kg to less than 9 kg;~* artesunate 50 mg / amodiaquine 135 mg: 1 tablet / day for 3 days for children with a weight of 9 kg to less than 18 kg;~* artesunate 100 mg / amodiaquine 270 mg: 1 tablet / day for 3 days for children with a weight of 18 kg to less than 36 kg;
Trial: NCT05822739
Drug: BBM-P002
RxNorm normalized name: BBMG
DrugBank: Bromothalonil (DB14199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic: single- dose intracranial injection of BBM-P002 Neurosurgical delivery of BBM-P002 to the brain
Trial: NCT04453059
Drug: Iopamidol
RxNorm normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previously administered Isovue-300 (300 mgI/mL) PO at a dilution of 2-3% (6-9 mgI/mL)
Trial: NCT00001005
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001005
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00236379
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Target oral dose of 20 milligrams per day for 6 months
Trial: NCT00236379
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target oral dose of 6 milligrams per day for for 6 months
Trial: NCT05487196
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine belongs to the drug classification of antihypertensives
Trial: NCT05487196
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine belongs to the drug classification of sedatives
Trial: NCT05487196
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine belongs to the drug classification of local or regional anesthesia for surgery and is used as standard of care
Trial: NCT05978206
Drug: Nandrolone Decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive nandrolone decanoate (1 ml, 50 mg/ml intramuscularly given per visit) or placebo
Trial: NCT05096520
Drug: 2% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2% lidocaine
Trial: NCT05543707
Drug: PBI-0451 (Pomotrelvir)
RxNorm normalized name: PBI-1402
DrugBank: PBI-1402 (DB05480)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 × 350 mg tablets administered orally twice daily (BID) (1400 mg/day) with food for 5 days (10 total doses)
Trial: NCT06649331
Drug: SHR-A1811
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A HER2-directed ADC, via intravenous (into the vein) infusion per protocol.
Trial: NCT06649331
Drug: SHR-A1921
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A TROP2-directed ADC, via intravenous (into the vein) infusion per protocol.
Trial: NCT06649331
Drug: SHR-A2009
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A HER3-directed ADC, via intravenous (into the vein) infusion per protocol.
Trial: NCT06649331
Drug: SHR-A2102
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Nectin4-directed ADC, via intravenous (into the vein) infusion per protocol.
Trial: NCT06378502
Drug: Amoxicillin Short
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short Span
Trial: NCT06378502
Drug: Amoxicillin Long
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long span
Trial: NCT06728514
Drug: Inj Bupivacaine
RxNorm normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inj Bupivacaine 0.25% (10ml) in both groups
Trial: NCT05400577
Drug: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
Trial: NCT05500677
Drug: Lidocaine topical
RxNorm normalized name: lidocaine topical
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine spray, which is a quick and easy-to-use topical local anesthetic, will be applied as a puff to the painful area.
Trial: NCT05083312
Drug: APT-1011
RxNorm normalized name: tetracycline
DrugBank: APT-101 (DB18003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
Trial: NCT04804813
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cabozantinib tablets
Trial: NCT04808752
Drug: Almonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients meeting the criteria for inclusion and exclusion were included in the high-dose almonertinib treatment group and received oral almonertinib 165 mg once a day.
Trial: NCT06214741
Drug: survodutide
RxNorm normalized name: Survodutide
DrugBank: Survodutide (DB18989)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once weekly subcutaneous injection
Trial: NCT03357419
Drug: Cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be randomized, at the operation day, to one of two treatment groups:~* group 1: prophylactic antibiotic~* group 2: placebo oral capsule~  * Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~ * Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses.
Trial: NCT06398028
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green has a sharply defined spectral peak absorption of near-infrared light at 800 nm in blood plasma or blood. This is the same wavelength at which the optical density of oxygenated hemoglobin in blood approximately equals that of reduced hemoglobin. Therefore, this coincidental light absorption makes it possible to measure indocyanine green concentrations in blood, plasma and serum in terms of its optical density at 800 nm, independent of variations in oxygen saturation level
Trial: NCT04453397
Drug: TNB-383B
RxNorm normalized name: TNB-383B
DrugBank: TNB-383B (DB17268)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.
Trial: NCT03649438
Drug: 131 I-Metaiodobenzylguanidine
DrugBank: Guanidine (DB00536)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Minimum dose of 10 mCi/kg for patients without a stem cell source whose renal function is above the upper limit of normal but still meets eligibility criteria.~* Dose of 12 mCi/kg for patients without a stem cell source with normal renal function and meets other eligibility criteria.~* Dose of \> 12 mCi/kg to 18 mCi/kg maximum at investigator's discretion for patients meeting eligibility criteria with stem cells available.
Trial: NCT03649438
Drug: Potassium Iodide
RxNorm normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection.
Trial: NCT03649438
Drug: G-csf
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally \>5000). This will start 24 hours after stem cell infusion (if stem cells are to be infused).
Trial: NCT05834582
Drug: Fluzoparib+Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluzoparib+Paclitaxel for 4 cycles if tumor response is SD after 2 cycles of EC induced chemotherapy
Trial: NCT00000990
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04890522
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maximum 6 cycles for combined therapy.
Trial: NCT04890522
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Maximum 6 cycles for combined therapy.
Trial: NCT04890522
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Maximum 6 cycles for combined therapy.
Trial: NCT00004442
Drug: ursodiol
RxNorm normalized name: Ursodiol
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00681148
Drug: Botox injection
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Intraprostatic injection of Botox (100 units for \< 30 cc prostate; 200 units for \> 30 cc prostate) administering 2 transperineal injections into both lateral lobes of the prostate (25-50 units per injection), just 5-10 mm proximal to the bladder neck.
Trial: NCT00681148
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection, administering 2 transperineal injections into both lateral lobes of the prostate (1-2 cc per injection), just 5-10 mm proximal to the bladder neck.
Trial: NCT05179070
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the first is the rapid up-titration group, which will get carvedilol up-titration every day, 3.125mg twice daily on the first day, 6.125mg twice daily on the second day, 12.5mg twice daily on the third day and 25mg twice daily on the fourth day consecutively. And the second group will have carvedilol titration according to established guidelines on Heart Failure, start 3.125mg twice daily, and up titrated every 2 weeks
Trial: NCT05217667
Drug: ARO-ANG 3 Injection
RxNorm normalized name: ARO-APOC3
DrugBank: ARO-ANG3 (DB17626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive ARO-ANG3 SC on Day 1 and Day 84 during the initial 36 Weeks of the study and on Day1 and Months 3, 6, 9, 12, 15, 18, and 21 of the extension period
Trial: NCT05510427
Drug: Infigratinib
RxNorm normalized name: INFIGRATINIB
DrugBank: Infigratinib (DB11886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by PO